Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

ConclusionsIn our analysis, patients with PsA receiving secukinumab were more likely to achieve higher ACR responses through 1  year (weeks 16–48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from FUTURE 2 and thus should be considered interim until the ongoing head-to-head RCT EXCEED can validate these findings.FundingNovartis Pharma AG.

Source: Rheumatology and Therapy - March 31, 2018 Category: Rheumatology Source Type: research